
	As of March 31, 2026		As of December 31, 2025
Laboratory equipment	$	7,857	$	8,563
Leasehold improvements	2,156		2,156
Furniture and fixtures	1,832		1,832
Computer equipment and software	1,105		1,105
Construction-in-progress	153		153
Total property and equipment, gross	13,103		13,809
Less: Accumulated depreciation	(10,439)		(10,869)
Total property and equipment, net	$	2,664	$	2,940

Depreciation expense was $0.3 million and $0.4 million for the three months ended March 31, 2026 and 2025, respectively.

In the fourth quarter of 2025, the Company committed to a plan to sell certain laboratory equipment that was no longer required following the restructuring of operations initiated May 1, 2025. Management determined that the assets met the criteria for classification as held for sale in accordance with ASC 360, "Property, Plant and Equipment."

The Company intended to divest these assets as part of their strategic realignment of resources, focusing on the development of PLN-101095 and the drug discovery platform. The assets were measured at the lower of their carrying value or fair value less cost to sell, and reclassified to "Property and equipment held for sale" within current assets on the Balance Sheets as of December 31, 2025. Depreciation ceased to be recognized on the assets after the date of its held-for-sale classification.


	As of March 31, 2026	As of December 31, 2025
Laboratory equipment held for sale	906	1,040
Total property and equipment held for sale	906	1,040